Investors Buy Large Volume of Tandem Diabetes Care Call Options (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors bought 6,339 call options on the stock. This represents an increase of 620% compared to the average daily volume of 880 call options.

Tandem Diabetes Care Trading Up 4.4 %

Shares of TNDM traded up $2.09 during trading on Tuesday, reaching $49.32. 4,898,555 shares of the company traded hands, compared to its average volume of 1,762,466. The stock has a 50-day simple moving average of $36.33 and a 200-day simple moving average of $28.50. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $52.51. The stock has a market cap of $3.19 billion, a PE ratio of -22.73 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. On average, analysts anticipate that Tandem Diabetes Care will post -1.7 earnings per share for the current year.

Institutional Trading of Tandem Diabetes Care

Institutional investors and hedge funds have recently bought and sold shares of the business. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care in the 4th quarter valued at about $27,000. Headlands Technologies LLC purchased a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at approximately $35,000. MCF Advisors LLC raised its holdings in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Signaturefd LLC lifted its position in shares of Tandem Diabetes Care by 871.8% during the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock worth $50,000 after purchasing an additional 1,517 shares during the last quarter. Finally, Arcadia Investment Management Corp MI lifted its position in shares of Tandem Diabetes Care by 141.6% during the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company's stock worth $66,000 after purchasing an additional 1,085 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TNDM shares. Wells Fargo & Company raised shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $21.00 to $45.00 in a report on Monday, April 29th. Stifel Nicolaus raised their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, April 23rd. SVB Leerink raised Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Robert W. Baird upped their price target on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a "neutral" rating in a research report on Friday, May 3rd. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $50.00 target price (up previously from $35.00) on shares of Tandem Diabetes Care in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $43.80.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.